




ROUNDTABLE FROM LAB TO CLINIC

Best practices in translational
medicine & innovation management

4th June 2013, European Parliament



Roundtable Partners



The BASTION project is funded by the European Commission within its Seventh Framework Programme and co-funded by the Polish Ministry of Science and Higher Education.

AGENDA

9:00 WELCOME COFFEE AND REGISTRATION

9:30 OPENING AND WELCOME ADDRESS

Jerzy Buzek, Member and former President of the European Parliament (video message)

Peter Wrobel, Founding Director, Science|Business

9:35 INTRODUCTIONS

Slawomir Majewski, Deputy Rector for Science and International Relations, Medical University of Warsaw

Jakub Golab, BASTION Project coordinator; Head of Department of Immunology, Medical University of Warsaw

9:50 CASE STUDIES OF COMMERCIALISATION OF RESEARCH RESULTS

Overview:

Olivier Lescroart, IPR Officer, KU Leuven R&D

Oncology:

Marcin Szumowski, Business Development Director, BioTechMed Cluster Mazovia; Head of International Cooperation, Nencki Institute

Regenerative medicine:

Daniela Couto, CEO, Cell2B; 2012 ACES finalist

Neurotechnology:

Sabine Bahn, Director of the Cambridge Centre for Neuropsychiatric Research, University of Cambridge; Chief Scientific Officer, Psynova Neurotech; 2011 ACES winner

An industry perspective:

Araz Raoof, Global Functional Head C.R.E.A.Te, Janssen Research & Development

11:00 COFFEE BREAK

11:30 BARRIERS TO TRANSLATIONAL RESEARCH IN EUROPE:
WHAT ARE THE CHALLENGES? WHAT ARE THE SOLUTIONS?

Open discussion

Main discussants:

Magda Chlebus, Director Science Policy, EFPIA

Arnd Hoeveler, Head of Unit - Advanced therapies and systems medicine, DG Research and Innovation, European Commission

Marta Czanik-Kawecka, Academic Center of Innovation, Medical University of Warsaw

A list of recommendations will be reported after the event by Science|Business.

12:30 CLOSING REMARKS

HONORARY PATRON



Jerzy Buzek
Member and
former President,
European Parliament



Sabine Bahn

Director of the Cambridge Centre for Neuropsychiatric Research, University of Cambridge; Chief Scientific Officer, Psynova Neurotech; 2011 ACES winner

Sabine Bahn is a practising psychiatrist, leading research scientist, Director of the Cambridge Centre for Neuropsychiatric Research at Cambridge University and Chair in Translational Neuropsychiatry at the Erasmus Medical Centre in Rotterdam, NL. Her main research interests are the molecular basis of neuropsychiatric disorders, with a focus on schizophrenia and mood disorders. Professor Bahn has published numerous articles in high impact journals over the last years. In 2005, she co-founded Psynova Neurotech Ltd., which, together with Rules Based Medicine (RBM), launched the first blood test aiding in the early diagnosis of Schizophrenia. In 2011 Psynova Neurotech and RBM were acquired by Myriad Genetics, a NASDAQ-listed company. Professor Bahn continues to be director and chief scientific officer for Psynova Neurotech as well as Senior Medical Director for Neuropsychiatric Disorders for Myriad RBM and Myriad Genetics.



Magda Chlebus

Director Science Policy, EFPIA

Magda Chlebus, Director Science Policy at the European Federation of Pharmaceutical Industries and Associations is in charge of policy and legislative debates which shape the European research environment. This includes public private collaborations (incl. the Innovative Medicines Initiative) and enabling and sensitive technologies. After a Master Degree in Applied Linguistics at University of Warsaw in 1992 and a career as a translator and teacher, in 1995 she joined EFPIA, the representative voice of the R&D-based pharmaceutical industry in Europe. Her experience covers public and government affairs with a focus on Brussels Village, including designing and implementing advocacy campaigns on EU legislation as well as implementation of the pharmaceutical legislation in new Member States.



Daniela Couto

CEO, Cell2B; 2012 ACES finalist

Daniela is currently CEO at Cell2B (www.cell2b.com), a biotechnology start-up dedicated to the development of a new line of healthcare therapies to treat organ rejection in patients undergoing transplants. She has been awarded several research grants and entrepreneurial awards, namely the Women Entrepreneur Award 2011. Cell2B was a finalist at the European Academic Enterprise Awards 2012 and received the €40,000 Evers Award 2012. Daniela graduated with the highest honors in Bioengineering in 2011 from Instituto Superior Técnico – Technical University of Lisbon, as part of the MIT-Portugal Program. Daniela developed her studies in technological innovation at Massachusetts Institute Technology for a total of 2 years. Her work resulted in strong literary contributions to the field of drug-device combination products, cell therapies and tissue engineering. Daniela holds a Master degree in Biomedical Engineering from University of Minho, Portugal, having worked in collaboration with Politecnico di Milano, in Italy.



Jakub Golab

BASTION Project coordinator, Head of Department of Immunology, Medical University of Warsaw

Jakub is the professor of medicine. His research is focused on experimental oncology, especially on improving anticancer activity of various therapeutic approaches, including proteasome inhibitors and statins. He is an expert in the fields of photodynamic therapy and monoclonal antibodies. Author or coauthor of around 100 of publications. Promoted 14 PhD students.

He is a member of the University Committee for Intellectual Property and the Council of the First Faculty of Medicine at MUW. Member of the Committee on Cell Biology, Committee on Immunology and Infectious Diseases, Commission on Tumor Biology in the Committee on Human Genetics and Molecular Pathology in the Polish Academy of Sciences. Member of the Scientific Advisory Board of the National Research Centre.



Arnd Hoeveler

Head of Unit - Advanced therapies and systems medicine, DG Research and Innovation, European Commission

Arnd Hoeveler received his PhD from the Institute of Genetics at the University of Cologne. In 1991 he was awarded a full Professorship in Biochemistry and Molecular Biology in France, where he served several positions before joining the Directorate-General for Research and Innovation at the European Commission in 1996.

Between 2001 and 2006 he served as Head of Unit, covering Infectious Diseases, and led several European programmes dealing with HIV/AIDS, Malaria and Tuberculosis. He is currently in charge of new therapies, systems medicine, predictive human safety assessments, trans-disease vaccinology and medical technology. He is a board member of the European Federation of Immunological Societies and serves on several International Advisory Boards.



Slawomir Majewski

BASTION Project Group Leader, Deputy Rector for Science and International Relations, Medical University of Warsaw

Professor of medicine, head of the Department of Dermatology and Venereology at Medical University of Warsaw, specialist in dermatology, venereology, and allergology. Author or co-author of over 700 papers. Supervisor of four habilitations. Promoted 20 PhD students.

Slawomir is a member of several national and international societies and scientific institutions including European Society of Dermatological Research, European Academy of Dermatology and Venereology, European Association for Cancer Research and American Association for Cancer Research. He is a member of the European Medical Research Councils, International Advisory Committee of the Archives of Dermatology, International Editorial Committee of the Journal of American Academy of Dermatology, Board of European Society for Dermatological Research and Polish Academy of Sciences.



Olivier Lescroart

IPR Officer, KU Leuven R&D

Olivier Lescroart holds a Master in Bio-engineering and a PhD in Applied Biological Sciences (KU Leuven, Belgium). From 2000 until 2008, he worked as Technology Transfer Officer at KU Leuven Research & Development.

In 2008 he joined Fugeia N.V., a start-up company active in the field of health and nutrition. Within Fugeia he was responsible for the management of the company's intellectual property and regulatory affairs.

In January 2009 Olivier moved back to KU Leuven, where he manages Work Package 3 of the FP7 Entente project, aiming at building a platform for the exchange of information and expertise between all stakeholders involved in knowledge transfer within the field of health.



Araz Raoof

Vice-President of Global Functional Head C.R.E.A.Te, Janssen Belgium

Araz is Vice-President of Global Functional Head C.R.E.A.Te at Janssen Belgium. She is a member of the C.R.E.A.Te GLT and of the Campus Beerse R&D.

She completed her PhD at KU Leuven and an International Executive MBA at Michael Smurfit Graduate School of Business, University College Dublin, Ireland. She is a former Vice President of EU Head C.R.E.A.Te and a former Senior Director of Global Preclinical Development, Tibotec, Belgium. She has been also the Head of In Vivo Pharmacology, Elan Corporation, Ireland.



Marcin Szumowski

Business Development
Director, BioTechMed Cluster
Mazovia; Head of International
Cooperation, Nencki Institute



Peter Wrobel

Founding Director,
Science|Business

Marcin Szumowski is business development director, BioTechMed Cluster Mazovia, President and CEO of a new drug discovery company- OncoArendi Therapeutics (www.oncoarendi.com). Following a successful research career in the United States of America, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed three start-ups, including now publicly traded Medicalgorithmics SA (www.medicalgorithmics.com), where he was President and CEO from 2005-2010. Since 2001 he has been head of the international relations and project management office at the Nencki Institute of Experimental Biology. Since 2012 he has been involved in Independent Expert Panels assisting the European Commission in impact assessment and interim evaluations of the Innovative Medicines Initiative (IMI) PPP.

Pete co-founded Science|Business in 2004 with Richard Hudson and was its first editorial director.

He now works on a variety of editorial projects within the company. From 1996 to 2004, Pete was managing editor of Nature.

He has 30 years of experience in writing and editing science journalism, including four years as head of publications at the UK Medical Research Council and eight years as chief sub-editor at New Scientist. He is a past chairman of the Association of British Science Writers.

About BASTION

BASTION (From Basic to Translational Research in Oncology) is a multidisciplinary project co-financed by the European Commission under the 7th Framework Programme- REGPOT 2012-2013.

The objective of the project is to build up the research potential of the Medical University of Warsaw (MUW) in the field of experimental oncology.

The scientific research of the highly professional BASTION project teams is focused on personalised medicine and the development of diagnostic and therapeutic methods customised to patients' individual needs.

The project also aims at reducing the time from scientific discovery to clinical application. Therefore much effort is put into increasing innovation within MUW and to support science and business



About ACES



The 2013 ACES take place in the European Parliament on 4 June. Now in their fifth year, the ACES are the only pan-European awards for enterprise in university and public research institutes.

They give public recognition to those researchers, engineers, professors, students and government officials in Europe who have done the most to foster a culture of enterprise on campus.

This can be through taking the risk of launching a spinout company, developing a discovery into a marketable innovation, or promoting policies that create a receptive environment for entrepreneurship on campus.

ACES draws nominations from all sectors, disciplines and countries in Europe, and are judged by the Science|Business Innovation Board, a leadership panel co-founded by Science|Business, business schools INSEAD and ESADE, in association with Microsoft and BP.



Finalists at the 2012 edition of the Academic Enterprise Awards

Programme presented by:


ACES 2013 Partners:



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Mission of Switzerland to the European Union





BASTION

FROM BASIC TO TRANSLATIONAL
RESEARCH IN ONCOLOGY

More information:

www.bastion.wum.edu.pl